1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
  4. > Chemotherapy Induced Nausea and Vomiting - Pipeline Review, H1 2016

Chemotherapy Induced Nausea and Vomiting - Pipeline Review, H1 2016

  • February 2016
  • -
  • Global Markets Direct
  • -
  • 100 pages

Chemotherapy Induced Nausea and Vomiting - Pipeline Review, H1 2016

Summary

Global Markets Direct’s, ‘Chemotherapy Induced Nausea and Vomiting - Pipeline Review, H1 2016’, provides an overview of the Chemotherapy Induced Nausea and Vomiting pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Chemotherapy Induced Nausea and Vomiting, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Chemotherapy Induced Nausea and Vomiting and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.


Scope

- The report provides a snapshot of the global therapeutic landscape of Chemotherapy Induced Nausea and Vomiting
- The report reviews pipeline therapeutics for Chemotherapy Induced Nausea and Vomiting by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Chemotherapy Induced Nausea and Vomiting therapeutics and enlists all their major and minor projects
- The report assesses Chemotherapy Induced Nausea and Vomiting therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Chemotherapy Induced Nausea and Vomiting

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Chemotherapy Induced Nausea and Vomiting
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Chemotherapy Induced Nausea and Vomiting pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table Of Contents

Chemotherapy Induced Nausea and Vomiting - Pipeline Review, H1 2016
Table of Contents
Table of Contents 2
List of Tables 6
List of Figures 7
Introduction 8
Global Markets Direct Report Coverage 8
Chemotherapy Induced Nausea and Vomiting Overview 9
Therapeutics Development 10
Pipeline Products for Chemotherapy Induced Nausea and Vomiting - Overview 10
Chemotherapy Induced Nausea and Vomiting - Therapeutics under Development by Companies 11
Chemotherapy Induced Nausea and Vomiting - Pipeline Products Glance 13
Late Stage Products 13
Clinical Stage Products 14
Early Stage Products 15
Unknown Stage Products 16
Chemotherapy Induced Nausea and Vomiting - Products under Development by Companies 17
Chemotherapy Induced Nausea and Vomiting - Companies Involved in Therapeutics Development 19
Acacia Pharma Limited 19
Aphios Corporation 20
Astellas Pharma Inc. 21
Athenex, Inc. 22
Helsinn Healthcare S.A. 23
Heron Therapeutics, Inc. 24
INSYS Therapeutics, Inc. 25
Kyowa Hakko Kirin Co., Ltd. 26
Merck and Co., Inc. 27
RedHill Biopharma Ltd. 28
SoluBest Ltd. 29
Suda Ltd 30
Tesaro, Inc. 31
Chemotherapy Induced Nausea and Vomiting - Therapeutics Assessment 32
Assessment by Monotherapy Products 32
Assessment by Combination Products 33
Assessment by Target 34
Assessment by Mechanism of Action 36
Assessment by Route of Administration 38
Assessment by Molecule Type 40
Drug Profiles 41
(netupitant + palonosetron hydrochloride) - Drug Profile 41
Product Description 41
Mechanism of Action 41
RandD Progress 41
(palonosetron hydrochloride + Pro-netupitant) - Drug Profile 43
Product Description 43
Mechanism of Action 43
RandD Progress 43
APD-403 - Drug Profile 44
Product Description 44
Mechanism of Action 44
RandD Progress 44
aprepitant - Drug Profile 45
Product Description 45
Mechanism of Action 45
RandD Progress 45
aprepitant - Drug Profile 47
Product Description 47
Mechanism of Action 47
RandD Progress 47
aprepitant - Drug Profile 48
Product Description 48
Mechanism of Action 48
RandD Progress 48
dronabinol - Drug Profile 49
Product Description 49
Mechanism of Action 49
RandD Progress 49
dronabinol - Drug Profile 50
Product Description 50
Mechanism of Action 50
RandD Progress 50
FK-886 - Drug Profile 51
Product Description 51
Mechanism of Action 51
RandD Progress 51
fosaprepitant dimeglumine - Drug Profile 53
Product Description 53
Mechanism of Action 53
RandD Progress 53
granisetron - Drug Profile 54
Product Description 54
Mechanism of Action 54
RandD Progress 54
granisetron ER - Drug Profile 55
Product Description 55
Mechanism of Action 55
RandD Progress 55
granisetron ER - Drug Profile 57
Product Description 57
Mechanism of Action 57
RandD Progress 57
granisetron hydrochloride - Drug Profile 59
Product Description 59
Mechanism of Action 59
RandD Progress 59
LPI-1504 - Drug Profile 60
Product Description 60
Mechanism of Action 60
RandD Progress 60
LPI-1505 - Drug Profile 61
Product Description 61
Mechanism of Action 61
RandD Progress 61
NB-1222 - Drug Profile 62
Product Description 62
Mechanism of Action 62
RandD Progress 62
netupitant - Drug Profile 63
Product Description 63
Mechanism of Action 63
RandD Progress 63
ondansetron hydrochloride - Drug Profile 64
Product Description 64
Mechanism of Action 64
RandD Progress 64
ondansetron hydrochloride - Drug Profile 66
Product Description 66
Mechanism of Action 66
RandD Progress 66
ondansetron hydrochloride - Drug Profile 67
Product Description 67
Mechanism of Action 67
RandD Progress 67
ondansetron hydrochloride CR - Drug Profile 68
Product Description 68
Mechanism of Action 68
RandD Progress 68
rolapitant hydrochloride - Drug Profile 70
Product Description 70
Mechanism of Action 70
RandD Progress 70
Chemotherapy Induced Nausea and Vomiting - Recent Pipeline Updates 72
Chemotherapy Induced Nausea and Vomiting - Dormant Projects 89
Chemotherapy Induced Nausea and Vomiting - Discontinued Products 91
Chemotherapy Induced Nausea and Vomiting - Product Development Milestones 92
Featured News and Press Releases 92
Feb 04, 2016: FDA Approves Merck's Single-Dose EMEND (fosaprepitant dimeglumine) for Injection, in Combination with Other Antiemetic Agents, for the Prevention of Delayed Nausea and Vomiting in Adults Receiving Moderately Emetogenic Chemotherapy 92
Feb 01, 2016: Biologics Announces New Oncology Partnership 93
Jan 15, 2016: Heron Therapeutics Notified by FDA That It Will Not Take Action on SUSTOL New Drug Application by the PDUFA Date 93
Dec 15, 2015: Swissmedic Approves Akynzeo (netupitant/palonosetron) for use in the Prevention of Chemotherapy Induced Nausea and Vomiting in Switzerland 93
Nov 16, 2015: OPKO Licensee TESARO Announces the Launch of VARUBI (Rolapitant) in the United States 94
Nov 13, 2015: Helsinn Group and Eisai Announce Inclusion of AKYNZEO in American Society of Clinical Oncology Antiemetics Guid 94
Oct 14, 2015: Helsinn's AKYNZEO (netupitant/palonosetron) nominated within the category “Best Pharmaceutical Agent of the Year” at The Galien Foundation Prix Award 95
Sep 28, 2015: Heron Therapeutics Announces Oral Presentation of Data from Completed Phase 3 MAGIC Study for SUSTOL at the ASCO Breast Cancer Symposium 96
Sep 24, 2015: TESARO Announces Inclusion of VARUBI (rolapitant) in NCCN Antiemesis Guidelines 97
Sep 22, 2015: Heron Therapeutics to Present Data From Completed Phase 3 MAGIC Study of SUSTOL at ASCO Breast Cancer Symposium 98
Appendix 99
Methodology 99
Coverage 99
Secondary Research 99
Primary Research 99
Expert Panel Validation 99
Contact Us 99
Disclaimer 100

List of Tables
Number of Products under Development for Chemotherapy Induced Nausea and Vomiting, H1 2016 10
Number of Products under Development by Companies, H1 2016 12
Comparative Analysis by Late Stage Development, H1 2016 13
Comparative Analysis by Clinical Stage Development, H1 2016 14
Comparative Analysis by Early Stage Development, H1 2016 15
Comparative Analysis by Unknown Stage Development, H1 2016 16
Products under Development by Companies, H1 2016 17
Products under Development by Companies, H1 2016 (Contd..1) 18
Chemotherapy Induced Nausea and Vomiting - Pipeline by Acacia Pharma Limited, H1 2016 19
Chemotherapy Induced Nausea and Vomiting - Pipeline by Aphios Corporation, H1 2016 20
Chemotherapy Induced Nausea and Vomiting - Pipeline by Astellas Pharma Inc., H1 2016 21
Chemotherapy Induced Nausea and Vomiting - Pipeline by Athenex, Inc., H1 2016 22
Chemotherapy Induced Nausea and Vomiting - Pipeline by Helsinn Healthcare S.A., H1 2016 23
Chemotherapy Induced Nausea and Vomiting - Pipeline by Heron Therapeutics, Inc., H1 2016 24
Chemotherapy Induced Nausea and Vomiting - Pipeline by INSYS Therapeutics, Inc., H1 2016 25
Chemotherapy Induced Nausea and Vomiting - Pipeline by Kyowa Hakko Kirin Co., Ltd., H1 2016 26
Chemotherapy Induced Nausea and Vomiting - Pipeline by Merck and Co., Inc., H1 2016 27
Chemotherapy Induced Nausea and Vomiting - Pipeline by RedHill Biopharma Ltd., H1 2016 28
Chemotherapy Induced Nausea and Vomiting - Pipeline by SoluBest Ltd., H1 2016 29
Chemotherapy Induced Nausea and Vomiting - Pipeline by Suda Ltd, H1 2016 30
Chemotherapy Induced Nausea and Vomiting - Pipeline by Tesaro, Inc., H1 2016 31
Assessment by Monotherapy Products, H1 2016 32
Assessment by Combination Products, H1 2016 33
Number of Products by Stage and Target, H1 2016 35
Number of Products by Stage and Mechanism of Action, H1 2016 37
Number of Products by Stage and Route of Administration, H1 2016 39
Number of Products by Stage and Molecule Type, H1 2016 40
Chemotherapy Induced Nausea and Vomiting Therapeutics - Recent Pipeline Updates, H1 2016 72
Chemotherapy Induced Nausea and Vomiting - Dormant Projects, H1 2016 89
Chemotherapy Induced Nausea and Vomiting - Dormant Projects (Contd..1), H1 2016 90
Chemotherapy Induced Nausea and Vomiting - Discontinued Products, H1 2016 91

List of Figures
Number of Products under Development for Chemotherapy Induced Nausea and Vomiting, H1 2016 10
Number of Products under Development by Companies, H1 2016 11
Comparative Analysis by Late Stage Development, H1 2016 13
Comparative Analysis by Clinical Stage Development, H1 2016 14
Comparative Analysis by Early Stage Products, H1 2016 15
Assessment by Monotherapy Products, H1 2016 32
Number of Products by Targets, H1 2016 34
Number of Products by Stage and Targets, H1 2016 34
Number of Products by Mechanism of Actions, H1 2016 36
Number of Products by Stage and Mechanism of Actions, H1 2016 36
Number of Products by Routes of Administration, H1 2016 38
Number of Products by Stage and Routes of Administration, H1 2016 38
Number of Products by Stage and Molecule Types, H1 2016 40

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
Tyrosine Protein Kinase Mer (Proto Oncogene c Mer or Receptor Tyrosine Kinase MerTK or MERTK or EC 2.7.10.1) - Pipeline Review, H2 2016

Tyrosine Protein Kinase Mer (Proto Oncogene c Mer or Receptor Tyrosine Kinase MerTK or MERTK or EC 2.7.10.1) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • August 2016
  • by Global Markets Direct

Tyrosine Protein Kinase Mer (Proto Oncogene c Mer or Receptor Tyrosine Kinase MerTK or MERTK or EC 2.7.10.1) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Tyrosine Protein Kinase Me ...

P27 (Negative Regulatory Factor or Nef) - Pipeline Review, H2 2016

P27 (Negative Regulatory Factor or Nef) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • August 2016
  • by Global Markets Direct

P27 (Negative Regulatory Factor or Nef) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘P27 (Negative Regulatory Factor or Nef) - Pipeline Review, H2 2016’, provides in depth analysis ...

Iduronate 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13) - Pipeline Review, H2 2016

Iduronate 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • August 2016
  • by Global Markets Direct

Iduronate 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Iduronate 2 Sulfatase (Alpha L Iduronate ...


ref:plp2016

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.